Dual trigger for final oocyte maturation in expected normal responders with a high immature oocyte rate: a randomized controlled trial

Frontiers in Medicine

Medicine

Meng-Han Yan¹  Jing-Yan Song²  Zhen-Gao Sun² 

[1] The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China;The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China;Reproductive Center of Integrated Medicine, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China;

关键词: normal ovarian responder;    dual trigger;    gonadotropin releasing hormone agonist;    human chorionic gonadotropin;    MII oocytes;   

DOI  :  10.3389/fmed.2023.1254982

 received in 2023-07-08, accepted in 2023-09-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectiveTo evaluate whether dual trigger could improve reproductive outcomes in women with low oocyte maturation rates compare to human chorionic gonadotropin (hCG) trigger.MethodsThis study included expected normal ovarian responders younger than 40 years old whose immature oocyte rate in the previous cycle was more than 50% at the reproductive center from July 2021 to November 2022. A total of 73 patients were enrolled at trigger, including 34 in the hCG trigger group and 39 in the dual trigger group (co-administration of gonadotrophin releasing hormone (GnRH) agonist and hCG, 40 and 34 h prior to oocyte retrieval, respectively). The primary outcome was oocyte maturation rate.ResultsThere was no significant difference in the number of oocytes retrieved between the two study groups, but the oocyte maturation rate was higher in dual trigger group (84.0% [14.0%] vs. 55.5% [19.8%], p < 0.001). Moreover, there were also higher cumulative pregnancy rate (69.4% vs. 40.0%, p = 0.035) and cumulative live birth rate (66.7% vs. 36.0%, p = 0.022) in dual trigger group.ConclusionFor normal responders with low oocyte maturation rates, the dual trigger may be more effective than the conventional hCG trigger.Clinical trial registrationClinicalTrials.gov, identifier ChiCTR2100049292.

【 授权许可】

Unknown   
Copyright © 2023 Yan, Sun and Song.